FDA OKs etravirine as treatment for HIV

The FDA has cleared etravirine, a non-nucleoside reverse transcriptase inhibitor, as combination treatment for HIV infection in adults who fail to respond to other antiretrovirals. Johnson & Johnson unit Tibotec Therapeutics will market the drug under the brand Intelence.

View Full Article in:

Boston Globe (tiered subscription model), The · NYTimes.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice-President of Technology and Regulatory Affairs
AdvaMed
Washington DC, DC
Sr Product Manager Global Marketing (US/DA/00/0085/SL) - 14000009V3
Abbott
Chicago, IL
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Vice President, Information Technology
HealthPartners
MN